<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Glob Health</journal-id><journal-id journal-id-type="iso-abbrev">J Glob Health</journal-id><journal-id journal-id-type="publisher-id">JGH</journal-id><journal-title-group><journal-title>Journal of Global Health</journal-title></journal-title-group><issn pub-type="ppub">2047-2978</issn><issn pub-type="epub">2047-2986</issn><publisher><publisher-name>International Society of Global Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">jogh-10-010377</article-id><article-id pub-id-type="doi">10.7189/jogh.10.010377</article-id><article-categories><subj-group subj-group-type="heading"><subject>Viewpoints</subject></subj-group></article-categories><title-group><article-title>Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Giammaria</surname><given-names>Daniele</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pajewski</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><label>1</label>Ophthalmology Department, Azienda &#x0201c;Ospedali Riuniti Marche Nord&#x0201d;, Pesaro, Italy</aff><aff id="aff2"><label>2</label>Gran Sasso Science Institute (GSSI), L&#x02019;Aquila, Italy</aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence to:</bold>&#x02028;Daniele Giammaria, MD&#x02028;Via dello Scalo 17/A&#x02028;61032 Fano (PU)&#x02028;Italy&#x02028;<email xlink:href="da.giamma@gmail.com">da.giamma@gmail.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="print"><month>6</month><year>2020</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>6</month><year>2020</year></pub-date><volume>10</volume><issue>1</issue><elocation-id>010377</elocation-id><permissions><copyright-statement>Copyright &#x000a9; 2020 by the Journal of Global Health. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License.</license-p></license></permissions><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="35"/><page-count count="5"/></counts></article-meta></front><body><p>In recent months, the pandemic caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) produced serious consequences in terms of both human lives lost and economic damage. For reasons still unclear, lethality rates reported for Coronavirus Disease-2019 (COVID-19) appear to differ significantly among countries [<xref rid="R1" ref-type="bibr">1</xref>]. Different health strategies for managing COVID-19 patients implemented in different countries may have played an important role in determining these lethality rates.</p><p>In most cases COVID-19 presents mild symptoms, and 50% of infected individuals are asymptomatic [<xref rid="R2" ref-type="bibr">2</xref>]. However, in about 20% of patients the disease causes severe clinical consequences that require hospitalization and, in some cases, intensive care [<xref rid="R3" ref-type="bibr">3</xref>]. The average time between the onset of symptoms and hospitalization is seven days [<xref rid="R4" ref-type="bibr">4</xref>]. These data confirm the clinical observation that patients with severe forms worsen to clinical conditions one week after the onset of symptoms, on average [<xref rid="R5" ref-type="bibr">5</xref>]. Individual factors influencing the natural history of the disease could cause such dissimilar clinical outcomes.</p><p>To date there are still no drugs officially approved for treatment of COVID-19. However, as already observed in SARS [<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>], it appears that early treatment with antiviral drugs could improve the natural history of COVID-19 [<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>]. Identifying in advance all subjects at risk of developing severe forms of COVID-19 and treating them with antivirals during early stages of infection could be one strategy to manage the pandemic.</p><p>COVID-19 appears to share several pathophysiological mechanisms with previous epidemics caused by SARS-CoV and Middle East Respiratory Syndrome (MERS)-CoV. As with SARS and MERS, the course of COVID-19 presents two phases: a first &#x0201c;viral&#x0201d; phase when cells are infected by the virus, the viral load increases rapidly and the host's immune response is triggered; and a second &#x0201c;immune&#x0201d; phase, which occurs in some patients only, when the immune system loses control of the inflammatory response, therefore causing serious damage to the lungs, kidneys and heart [<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>]. A common feature of coronaviruses is to replicate very quickly both in vitro and in vivo [<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref>]. In SARS-CoV infections, high viral loads measured in early stages of the disease are associated with increased mortality [<xref rid="R13" ref-type="bibr">13</xref>]. Both SARS-CoV and MERS-CoV are able to evade the host's initial immune response by interfering with the synthesis of interferon (INF) I and by inducing apoptosis of T lymphocytes [<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref>]. T lymphocytes play a fundamental role in generating an immune response to the virus and in modulating the inflammatory response of monocytes-macrophages [<xref rid="R16" ref-type="bibr">16</xref>]. Studies in animal models of SARS-CoV infection have shown that intense virus replication associated with reduced production of INF I during early stages of infection are associated with subsequent development of lung damage and with increased lethality [<xref rid="R15" ref-type="bibr">15</xref>]. The host's delayed immune response associated with increased viral replication promotes a progressive accumulation of inflammatory cells such as monocyte-macrophages, dendritic cells and neutrophils [<xref rid="R17" ref-type="bibr">17</xref>] in the lung tissue. When these cells are not appropriately modulated, the &#x0201c;immune&#x0201d; phase of the disease is triggered and a &#x0201c;cytokine storm&#x0201d; is generated [<xref rid="R18" ref-type="bibr">18</xref>].</p><p>Individual factors play a key role in the natural history of COVID-19. As already observed in SARS [<xref rid="R19" ref-type="bibr">19</xref>] and MERS [<xref rid="R20" ref-type="bibr">20</xref>], the most serious and lethal forms of COVID-19 are much more frequent in elderly patients, in males, and in individuals already affected by other pathologies. Epidemiological data collected in Italy at the time of this article shows that 95% of all deceased COVID-19 patients were &#x02265;60 years of age and that 65.3% were males. Out of 1738 deceased patients for whom it was possible to examine clinical data, 82% had two or more pathologies, and the number of those suffering from a single pathology was four times the number of those with no pre-existing pathologies [<xref rid="R21" ref-type="bibr">21</xref>]. A recent meta-analysis of thirteen retrospective studies conducted in China (on a total of 3027 patients) has shown that age &#x0003e;65 years is a risk factor for the development of severe forms / mortality from COVID-19 with an odds ratio (OR) of 6.06; according to the same study, male sex results in a risk factor with an OR of 1.76, while the following pathologies constitute independent risk factors for severe forms/ mortality from COVID: hypertension (OR&#x02009;=&#x02009;2.72), diabetes (OD&#x02009;=&#x02009;3.68), cardiovascular disease (OR&#x02009;=&#x02009;5.19), respiratory disease (OR&#x02009;=&#x02009;5.15) [<xref rid="R22" ref-type="bibr">22</xref>]. Another meta-analysis of six studies conducted in China (on a total of 1558 patients) confirmed that the previous pathologies, as well as cerebrovascular disease (OR&#x02009;=&#x02009;3.89), constitute independent risk factors for severe forms / mortality from COVID [<xref rid="R23" ref-type="bibr">23</xref>].</p><p>On the basis of these data, we have developed an algorithm to identify individuals at risk of developing severe or lethal forms of COVID-19. The algorithm uses three parameters: age, sex and comorbidity. Risk factors are: age &#x02265;65 years, male sex, and the presence of at least one of the following pathologies: hypertension, diabetes, respiratory diseases, cardiovascular disease, cerebrovascular disease. Subjects with at least two of these three factors are considered at risk (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Algorithm for the identification of subjects at high risk of developing severe forms of COVID-19</p></caption><table frame="hsides" rules="groups"><col width="165" span="1"/><col width="167" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Parameters</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Risk factors</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;65 years<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sex<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Male<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Comorbidity<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">1 or more diseases*<hr/></td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">Risk assessment</td><td valign="top" align="left" rowspan="1" colspan="1">1 out of 3 (low risk patient)<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">&#x02265;2 out of 3 (high risk patient)</td></tr></tbody></table><table-wrap-foot><p>*Hypertension, diabetes, cardiovascular disease, respiratory diseases, cerebrovascular disease [<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>].</p></table-wrap-foot></table-wrap><p>Individuals at risk could be sorted from national or regional health databases through simple search filters. General practitioners working in the first line of home intervention could thus identify subjects at risk among their patients. General practitioners could then verify the health conditions of patients, instruct them on COVID-19 symptoms (fever, cold, anosmia, sore throat, cough, etc.) and evaluate them in order to establish their suitability for antiviral therapy (eg, considering interference with other drugs, contraindications, etc.).</p><p>There are hundreds of clinical trials for SARS-CoV-2 therapies currently under way, and many involve drugs previously used against SARS-CoV and MERS-CoV [<xref rid="R24" ref-type="bibr">24</xref>]. Preliminary studies conducted on patients with COVID-19 show that early treatment with antivirals can reduce patient mortality, while late-stage treatment does not improve survival [<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>]. The biphasic nature of COVID-19, as already shown in SARS [<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>], could explain why treatments with antiviral drugs are useful just during the first phase of the disease.</p><p>Because of the current pandemic crisis, while awaiting the first results of trials, several antiviral treatments are being administered to patients with moderate and severe forms of COVID-19 [<xref rid="R25" ref-type="bibr">25</xref>]. A few days may elapse between the onset of symptoms and the clinical worsening of the disease; according to reported data, hospitalization takes place, on average, seven days after the onset of symptoms [<xref rid="R4" ref-type="bibr">4</xref>]. Therefore, most patients begin antiviral therapy only within hospitals. The delay between the onset of symptoms and the administration of antiviral drugs could reduce the effectiveness of these treatments [<xref rid="R8" ref-type="bibr">8</xref>]. For individuals at risk, treatment with antivirals should therefore start at home as early as possible after the onset of symptoms. Ideally, high-risk patients should start treatment immediately after disease is confirmed by nasopharyngeal swabs. However, if it is expected that the result of the swab cannot be available within 48-72 hours from the onset of symptoms, it may be ethically correct to start treatment earlier in highly suspicious cases: patients at risk who came into contact with COVID-19 patients in the previous 14 days and patients at risk with flu-like symptoms but previously vaccinated for influenza. In these cases, whether or not to continue with therapy would depend on results of nasopharyngeal swabs and / or on the evolution of patients' clinical conditions.</p><fig id="Fa" fig-type="figure" orientation="portrait" position="float"><caption><p>Photo: Image by Gerd Altmann from <ext-link ext-link-type="uri" xlink:href="https://pixabay.com/illustrations/covid-19-coronavirus-4908692/">Pixabay</ext-link>.</p></caption><graphic xlink:href="jogh-10-010377-Fa"/></fig><p>Antiviral drugs used for early home treatment of patients at risk should meet the following requirements: a) must have already shown to have antiviral activity against the most pathogenic CoVs; b) must be already on the market and immediately available to the whole population; c) must have a good safety profile; and d) must be suitable for home use.</p><p>To date, only a few drugs are potential candidates for meeting all the requirements above: Chloroquine (CH), its analogue Hydroxychloroquine (HCH), and the combination Lopinavir (LPV) / Ritonavir (RTV). These drugs have been shown to have good antiviral activity on CoVs, especially during in vitro studies [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R26" ref-type="bibr">26</xref>-<xref rid="R29" ref-type="bibr">29</xref>]. Unfortunately, there are only a few clinical studies [<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref>], which &#x02013; although encouraging &#x02013; provide a sufficient grade of recommendation only if considered within the context of a serious emergency such as the current pandemic. A multinational hospital registry analysis recently highlighted the potential cardiologic risks of CH/HCH used to treat hospitalized COVID-19 patients [<xref rid="R32" ref-type="bibr">32</xref>]. In order to mitigate risks for patients, early home therapy would be conditional to a clinical evaluation of possible effects on pre-existing pathologies and of possible interactions with other drugs. For patients with macular degeneration, for example, it would be preferable to use LPV/RTV rather than CH/HCH even if the risk of worsening retinal disease in short-term treatments with HCH is low [<xref rid="R33" ref-type="bibr">33</xref>]. CH/HCH should not be prescribed at home if patients have QT prolongation or a predisposition to this condition [<xref rid="R34" ref-type="bibr">34</xref>]. Any other antiviral drug that will be proven to be effective for treatment of COVID-19, while maintaining the aforementioned characteristics of availability, safety, and ease of handling, could be considered for early treatment of patients at risk.</p><p>As with most strategies, starting early treatment for large numbers of patients with risk factors would imply some drawbacks. As mentioned above, risks from side effects could be minimized through clinical evaluation by general practitioners and by prescribing drugs with a long and well documented history of use. The potential benefits of early treatment for patients at risk of developing serious or lethal forms of COVID-19 should therefore exceed other clinical concerns. From an economic point of view, any reduction in the number of patients requiring intensive care would result in a significant advantage, since daily cost of intensive care with mechanical ventilation can exceed US$10&#x02009;000 [<xref rid="R35" ref-type="bibr">35</xref>]. Even when prescribed to a large number of patients, the financial costs of therapies involving generic drugs like LPV/RTV or CH/HCH would be quite low. Implementation of the proposed strategy would also require a significant logistic effort, but coordinating general practitioners on a large scale and analyzing patient databases are activities of a magnitude comparable to those already being implemented to address the current pandemic in most countries.</p><p>In conclusion, COVID-19 is a pathology with important analogies to SARS and MERS. Previous studies on these two viruses are an important scientific legacy that could allow us to gain valuable time during a public health emergency. The subjects most at risk for COVID-19 are elderly males with pre-existing pathologies. Further studies will be needed to confirm the validity of the risk factors used in our algorithm. Both the cutoff used for age and the type and / or number of comorbidities could be modified if results from studies with larger samples or from other regions of the world become available. Early antiviral treatment of symptomatic patients at risk could result in a reduction in the numbers of hospitalizations and intensive care treatments and, therefore, of the related costs incurred by public health systems. In order to better manage the current COVID-19 pandemic, it would be appropriate to conduct a short-term formal assessment of a public health strategy based on the identification of subjects at risk and the treatment with antivirals during early stages of disease.</p></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> None.</p></fn><fn fn-type="other"><p><bold>Authorship contributions:</bold> All authors contributed to writing and conceptualizing the manuscript.</p></fn><fn fn-type="COI-statement"><p><bold>Competing interests:</bold> The authors completed the ICMJE Unified Competing Interest form (available upon request from the corresponding author), and declare no conflicts of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giangreco</surname><given-names>G</given-names></name></person-group><article-title>Case fatality rate analysis of Italian COVID-19 outbreak.</article-title>
<source>J Med Virol</source>. <year>2020</year> Apr 16. <pub-id pub-id-type="doi">10.1002/jmv.25894</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizumoto</surname><given-names>K</given-names></name><name><surname>Kagaya</surname><given-names>K</given-names></name><name><surname>Zarebski</surname><given-names>A</given-names></name><name><surname>Chowell</surname><given-names>G</given-names></name></person-group><article-title>Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.</article-title>
<source>Euro Surveill</source>. <year>2020</year>;<volume>25</volume>:<elocation-id>2000180</elocation-id>. <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.10.2000180</pub-id><?supplied-pmid 32183930?><pub-id pub-id-type="pmid">32183930</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="web">Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. <ext-link ext-link-type="uri" xlink:href="https://jamanetwork.com/journals/jama/fullarticle/2762130">https://jamanetwork.com/journals/jama/fullarticle/2762130</ext-link>.</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Shih</surname><given-names>TP</given-names></name><name><surname>Ko</surname><given-names>WC</given-names></name><name><surname>Tang</surname><given-names>HJ</given-names></name><name><surname>Hsueh</surname><given-names>PR</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19). The epidemic and the challenges.</article-title>
<source>Int J Antimicrob Agents</source>. <year>2020</year>;<volume>55</volume>:<elocation-id>105924</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105924</pub-id><?supplied-pmid 32081636?><pub-id pub-id-type="pmid">32081636</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical and immunological features of severe and moderate coronavirus disease 2019.</article-title>
<source>J Clin Invest</source>.<year> 2004</year>;<volume>130</volume>:<fpage>2620</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1172/JCI137244</pub-id><?supplied-pmid 32217835?><pub-id pub-id-type="pmid">32217835</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Lai</surname><given-names>ST</given-names></name><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Tsui</surname><given-names>E</given-names></name><name><surname>Tam</surname><given-names>CY</given-names></name><name><surname>Wong</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.</article-title>
<source>Hong Kong Med J</source>. <year>2003</year>;<volume>9</volume>:<fpage>399</fpage>-<lpage>406</lpage>.<?supplied-pmid 14660806?><pub-id pub-id-type="pmid">14660806</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Wong</surname><given-names>MM</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Chan</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.</article-title>
<source>Thorax</source>. <year>2004</year>;<volume>59</volume>:<fpage>252</fpage>-<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1136/thorax.2003.012658</pub-id><?supplied-pmid 14985565?><pub-id pub-id-type="pmid">14985565</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><etal/></person-group><article-title>A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.</article-title>
<source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>1787</fpage>-<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id><?supplied-pmid 32187464?><pub-id pub-id-type="pmid">32187464</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).</article-title>
<source>J Intern Med</source>. <year>2020</year>.<comment>Online ahead of print</comment>. <pub-id pub-id-type="doi">10.1111/joim.13063</pub-id><?supplied-pmid 32220033?><pub-id pub-id-type="pmid">32220033</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>MJ</given-names></name><name><surname>Bermejo-Martin</surname><given-names>JF</given-names></name><name><surname>Danesh</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>MP</given-names></name><name><surname>Kelvin</surname><given-names>DJ</given-names></name></person-group><article-title>Human immunopathogenesis of severe acute respiratory syndrome (SARS).</article-title>
<source>Virus Res</source>. <year>2008</year>;<volume>133</volume>:<fpage>13</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.02.014</pub-id><?supplied-pmid 17374415?><pub-id pub-id-type="pmid">17374415</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>SF</given-names></name><name><surname>Ho</surname><given-names>YC</given-names></name></person-group><article-title>SARS-CoV-2: a storm is raging.</article-title>
<source>J Clin Invest</source>. <year>2020</year>;<volume>130</volume>:<fpage>2202</fpage>-<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1172/JCI137647</pub-id><?supplied-pmid 32217834?><pub-id pub-id-type="pmid">32217834</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>ML</given-names></name><name><surname>Tan</surname><given-names>SH</given-names></name><name><surname>See</surname><given-names>EE</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name><name><surname>Ling</surname><given-names>AE</given-names></name></person-group><article-title>Proliferative growth of SARS coronavirus in Vero E6 cells.</article-title>
<source>J Gen Virol</source>. <year>2003</year>;<volume>84</volume>:<fpage>3291</fpage>-<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.19505-0</pub-id><?supplied-pmid 14645910?><pub-id pub-id-type="pmid">14645910</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Wong</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Initial viral load and the outcomes of SARS.</article-title>
<source>CMAJ</source>. <year>2004</year>;<volume>171</volume>:<fpage>1349</fpage>-<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.1040398</pub-id><?supplied-pmid 15557587?><pub-id pub-id-type="pmid">15557587</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiel</surname><given-names>V</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name></person-group><article-title>Interferon and cytokine responses to SARS-coronavirus infection.</article-title>
<source>Cytokine Growth Factor Rev</source>. <year>2008</year>;<volume>19</volume>:<fpage>121</fpage>-<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr.2008.01.001</pub-id><?supplied-pmid 18321765?><pub-id pub-id-type="pmid">18321765</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Vijay</surname><given-names>R</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Dysregulated Type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice.</article-title>
<source>Cell Host Microbe</source>. <year>2016</year>;<volume>19</volume>:<fpage>181</fpage>-<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.01.007</pub-id><?supplied-pmid 26867177?><pub-id pub-id-type="pmid">26867177</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KD</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Auh</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Adaptive immune cells temper initial innate responses.</article-title>
<source>Nat Med</source>. <year>2007</year>;<volume>13</volume>:<fpage>1248</fpage>-<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1038/nm1633</pub-id><?supplied-pmid 17891146?><pub-id pub-id-type="pmid">17891146</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindler</surname><given-names>E</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name></person-group><article-title>SARS-CoV and IFN: Too Little, Too Late.</article-title>
<source>Cell Host Microbe</source>. <year>2016</year>;<volume>19</volume>:<fpage>139</fpage>-<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.01.012</pub-id><?supplied-pmid 26867172?><pub-id pub-id-type="pmid">26867172</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Lam</surname><given-names>CW</given-names></name><name><surname>Wu</surname><given-names>AK</given-names></name><name><surname>Ip</surname><given-names>WK</given-names></name><name><surname>Lee</surname><given-names>NL</given-names></name><name><surname>Chan</surname><given-names>IH</given-names></name><etal/></person-group><article-title>Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.</article-title>
<source>Clin Exp Immunol</source>. <year>2004</year>;<volume>136</volume>:<fpage>95</fpage>-<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.2004.02415.x</pub-id><?supplied-pmid 15030519?><pub-id pub-id-type="pmid">15030519</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>GM</given-names></name><name><surname>Hedley</surname><given-names>AJ</given-names></name><name><surname>Ho</surname><given-names>LM</given-names></name><name><surname>Chau</surname><given-names>P</given-names></name><name><surname>Wong</surname><given-names>IOL</given-names></name><name><surname>Thach</surname><given-names>TQ</given-names></name><etal/></person-group><article-title>The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients.</article-title>
<source>Ann Intern Med</source>. <year>2004</year>;<volume>141</volume>:<fpage>662</fpage>-<lpage>73</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-141-9-200411020-00006</pub-id><?supplied-pmid 15520422?><pub-id pub-id-type="pmid">15520422</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivers</surname><given-names>CM</given-names></name><name><surname>Majumder</surname><given-names>MS</given-names></name><name><surname>Lofgren</surname><given-names>ET</given-names></name></person-group><article-title>Risks of death and severe disease in patients with Middle East Respiratory Syndrome Coronavirus, 2012-2015.</article-title>
<source>Am J Epidemiol</source>. <year>2016</year>;<volume>184</volume>:<fpage>460</fpage>-<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kww013</pub-id><?supplied-pmid 27608662?><pub-id pub-id-type="pmid">27608662</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="web">SARS-CoV-2 Surveillance Group. Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on April 16th 2020. Available: <ext-link ext-link-type="uri" xlink:href="https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_16_april_2020.pdf">https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_16_april_2020.pdf</ext-link>, 2020. Accessed: 18 April 2020.</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Risk factors of critical &#x00026; mortal COVID-19 cases: A systematic literature review and meta-analysis.</article-title>
<source>J Infect</source>. <year>2020</year> Apr 23:S0163-4453(20)30234-6. .<pub-id pub-id-type="doi">10.1016/j.jinf.2020.04.021</pub-id><?supplied-pmid 32335169?><pub-id pub-id-type="pmid">32335169</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis.</article-title>
<source>Aging (Albany NY)</source>. <year>2020</year>;<volume>12</volume>:<fpage>6049</fpage>-<lpage>57</lpage>.<?supplied-pmid 32267833?><pub-id pub-id-type="pmid">32267833</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>MA</given-names></name></person-group><article-title>Compounds with therapeutic potential against novel respiratory 2019 coronavirus.</article-title>
<source>Antimicrob Agents Chemother</source>. <year>2020</year>;<volume>64</volume>:<elocation-id>e00399-20</elocation-id>. <pub-id pub-id-type="doi">10.1128/AAC.00399-20</pub-id><?supplied-pmid 32152082?><pub-id pub-id-type="pmid">32152082</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV).</article-title>
<source>Nat Rev Drug Discov</source>. <year>2020</year>;<volume>19</volume>:<fpage>149</fpage>-<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/d41573-020-00016-0</pub-id><?supplied-pmid 32127666?><pub-id pub-id-type="pmid">32127666</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>MJ</given-names></name><name><surname>Bergeron</surname><given-names>E</given-names></name><name><surname>Benjannet</surname><given-names>S</given-names></name><name><surname>Erickson</surname><given-names>BR</given-names></name><name><surname>Rollin</surname><given-names>PE</given-names></name><name><surname>Ksiazek</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.</article-title>
<source>Virol J</source>. <year>2005</year>;<volume>2</volume>:<fpage>69</fpage>. <pub-id pub-id-type="doi">10.1186/1743-422X-2-69</pub-id><?supplied-pmid 16115318?><pub-id pub-id-type="pmid">16115318</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><etal/></person-group><article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).</article-title>
<source>Clin Infect Dis</source>. <year>2020</year>;<elocation-id>ciaa237</elocation-id>. <comment>Online ahead of print</comment>. <pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id><?supplied-pmid 32150618?><pub-id pub-id-type="pmid">32150618</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.</article-title>
<source>Cell Discov</source>. <year>2020</year>;<volume>6</volume>:<fpage>16</fpage>. <pub-id pub-id-type="doi">10.1038/s41421-020-0156-0</pub-id><?supplied-pmid 32194981?><pub-id pub-id-type="pmid">32194981</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>KT</given-names></name><name><surname>Wong</surname><given-names>AY</given-names></name><name><surname>Kaewpreedee</surname><given-names>P</given-names></name><name><surname>Sia</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Hui</surname><given-names>KPY</given-names></name><etal/></person-group><article-title>Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.</article-title>
<source>Antiviral Res</source>. <year>2020</year>;<volume>178</volume>:<elocation-id>104786</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104786</pub-id><?supplied-pmid 32251767?><pub-id pub-id-type="pmid">32251767</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name></person-group><article-title>Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).</article-title>
<source>Biosci Trends</source>. <year>2020</year>;<volume>14</volume>:<fpage>156</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.5582/bst.2020.03072</pub-id><?supplied-pmid 32281583?><pub-id pub-id-type="pmid">32281583</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P</given-names></name><name><surname>Lagier</surname><given-names>JC</given-names></name><name><surname>Parola</surname><given-names>P</given-names></name><name><surname>Hoang</surname><given-names>VT</given-names></name><name><surname>Meddeb</surname><given-names>L</given-names></name><name><surname>Sevestre</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.</article-title>
<source>Travel Med Infect Dis</source>. <year>2020</year>;<volume>34</volume>:<elocation-id>101663</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101663</pub-id><?supplied-pmid 32289548?><pub-id pub-id-type="pmid">32289548</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehra</surname><given-names>MR</given-names></name><name><surname>Desai</surname><given-names>SS</given-names></name><name><surname>Ruschitzka</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>AN</given-names></name></person-group><article-title>Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.</article-title>
<source>Lancet</source>. <year>2020</year>:S0140-6736(20)31180-6.<?supplied-pmid 32450107?><pub-id pub-id-type="pmid">32450107</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marmor</surname><given-names>MF</given-names></name><name><surname>Kellner</surname><given-names>U</given-names></name><name><surname>Lai</surname><given-names>TY</given-names></name><name><surname>Melles</surname><given-names>RB</given-names></name><name><surname>Mieler</surname><given-names>WF</given-names></name></person-group><article-title>Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision).</article-title>
<source>Ophthalmology</source>. <year>2016</year>;<volume>123</volume>:<fpage>1386</fpage>-<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.ophtha.2016.01.058</pub-id><?supplied-pmid 26992838?><pub-id pub-id-type="pmid">26992838</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Cremades</surname><given-names>M</given-names></name><name><surname>Solans</surname><given-names>BP</given-names></name><name><surname>Hughes</surname><given-names>E</given-names></name><name><surname>Ernest</surname><given-names>JP</given-names></name><name><surname>Wallender</surname><given-names>E</given-names></name><name><surname>Aweeka</surname><given-names>F</given-names></name><etal/></person-group><article-title>Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing.</article-title>
<source>Clin Pharmacol Ther</source>. <year>2020</year>. <comment>Online ahead of print</comment>. <pub-id pub-id-type="doi">10.1002/cpt.1856</pub-id><?supplied-pmid 32285930?><pub-id pub-id-type="pmid">32285930</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasta</surname><given-names>JF</given-names></name><name><surname>McLaughlin</surname><given-names>TP</given-names></name><name><surname>Mody</surname><given-names>SH</given-names></name><name><surname>Piech</surname><given-names>CT</given-names></name></person-group><article-title>Daily cost of an intensive care unit day: the contribution of mechanical ventilation.</article-title>
<source>Crit Care Med</source>. <year>2005</year>;<volume>33</volume>:<fpage>1266</fpage>-<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1097/01.CCM.0000164543.14619.00</pub-id><?supplied-pmid 15942342?><pub-id pub-id-type="pmid">15942342</pub-id></mixed-citation></ref></ref-list></back></article>